Key facts
as of Sep 2026- Cranebio’s last known valuation is $12.7M (Jul 2025).
- It has raised $4.8M; the latest was Early Stage VC ($2.6M) in Jul 2025.
- Notable investors include Nippon Venture Capital, Regional Economy Vitalization Corporation of Japan, AGS Consulting, Akigin Capital Partners, Axil Capital Partners — 6 tracked in total.
- 2 institutional filers report fund marks on Cranebio across 14 filings.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Cranebio
- ·The full record, as it builds
Recorded secondary trades
No secondary trades in Cranebio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
2 filers · latest Jun 20262 SEC-registered funds reported 14 fair-value marks on Cranebio between Apr 2025 and Jun 2026. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
No funding rounds for Cranebio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cranebio
Developer of medical testing systems intended to provide simple, sensitive and affordable medical testing kits. The company develops viral or bacterial gene testing kits and wearable testing kits focused on hormones and diseases peculiar to women, enabling female users to access an epoch-making product that does not require the troublesome collection of blood and urine.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2021
- Employees
- 11
- Website
- crane-bio.com/
- Ownership
- Privately Held (backing)